Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Pathologic Complete Response × Irinotecan × Clear all

Phase

Phase 3 1 Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 60 Colonic Neoplasms 25 Rectal Neoplasms 24 Neoplasm Metastasis 13 Stomach Neoplasms 10 Pancreatic Neoplasms 9 Neoplasms 6 Esophageal Squamous Cell Carcinoma 6 Esophageal Neoplasms 6 Small Cell Lung Carcinoma 5 Rhabdomyosarcoma 4 Intestinal Neoplasms 4 Gastrointestinal Neoplasms 4 Digestive System Neoplasms 4 Uterine Cervical Neoplasms 3 Sarcoma 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Cholangiocarcinoma 3 Rectal Diseases 2 Neoplasms by Histologic Type 2 Intestinal Diseases 2 Gastrointestinal Diseases 2 Digestive System Diseases 2 Colorectal Adenocarcinoma 2 Colonic Diseases 2 Carcinoma 2 Adenocarcinoma Of Esophagus 2 Solid Tumors 1 Sarcoma, Ewing 1 Rhabdomyosarcoma, Embryonal 1

Interventions

Cyclophosphamide 3 Epirubicin 2 Docetaxel 2 Carboplatin 2 Capecitabine 2 Azacitidine 2 venetoclax 1 tegafur-gimeracil-oteracil 1 taxane 1 sargramostim 1 ruxolitinib 1 rucaparib 1 pirarubicin 1 pertuzumab 1 pembrolizumab 1 olaparib 1 cc-486 1 Trastuzumab 1 Thalidomide 1 Radiotherapy 1 Radiation 1 Platinum 1 Paclitaxel 1 Oxaliplatin 1 Observation 1 Nivolumab 1 Monatide (IMS 3015) 1 Methotrexate 1 Magnetic Resonance Imaging 1 Leucovorin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07472868 2026-03-16

MEND-IT II

Catharina Ziekenhuis Eindhoven

Phase 3 Not yet recruiting

Pathologic Complete Response

Data powered by HemOnc (CC BY 4.0) Colophon ⚡